Every Form 4 that Perspective Therapeutics, Inc. (CATX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CATX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CATX filings page.
Perspective Therapeutics, Inc. (CATX) reported that Lantheus Alpha Therapy, LLC, a ten percent owner, sold shares of its common stock in open-market transactions on September 3 and September 4, 2026. The sales totaled 247,932 shares of common stock at weighted average prices around $3.11–$3.15 per share.
The shares are directly held by Lantheus Alpha Therapy, LLC, which is an indirect wholly owned subsidiary of Lantheus Holdings, Inc. Under SEC rules, Lantheus Holdings, Inc. may be deemed to have indirect beneficial ownership of these shares through Lantheus Alpha Therapy, LLC.
Perspective Therapeutics, Inc. (CATX) reported that significant stockholder Lantheus Alpha Therapy, LLC sold 42,129 shares of CATX common stock on September 2, 2026 in an open-market or private transaction at a weighted average price of $3.1147 per share, with individual trade prices ranging from $3.025 to $3.235. After this sale, Lantheus Alpha Therapy, LLC directly holds 11,521,296 CATX shares, and Lantheus Holdings, Inc., as its indirect parent, may be deemed to have indirect beneficial ownership of those shares under SEC rules.
Perspective Therapeutics, Inc. (CATX) disclosed that Lantheus Alpha Therapy, LLC, a ten percent owner and subsidiary of Lantheus Holdings, Inc., reported selling a total of 113,914 shares of CATX common stock in open-market or private transactions on August 31 and September 1, 2026. The August 31 sale covered 78,145 shares at a weighted average price of $3.143 per share, with individual trades between $3.095 and $3.165. The September 1 sale covered 35,769 shares at a weighted average price of $3.1193, with trades between $3.08 and $3.165. The share amounts reflect Perspective Therapeutics’ 1-for-10 reverse stock split effective June 14, 2024, and the filing notes that Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held directly by Lantheus Alpha Therapy.
Perspective Therapeutics, Inc. (CATX) had a significant shareholder, Lantheus Holdings, Inc., report the sale of 35,769 shares of common stock on September 1, 2026 in a sale transaction. The weighted average sale price was $3.1193 per share, with individual trades between $3.08 and $3.165 per share.
After this transaction, an affiliated entity, Lantheus Alpha Therapy, LLC, directly held 11,563,425 shares of CATX common stock, and Lantheus Holdings may be deemed to have indirect beneficial ownership of those shares. No Rule 10b5-1 trading plan is reported for this sale.
Perspective Therapeutics, Inc. (CATX) had a significant shareholder, Lantheus Holdings, Inc., report that its wholly owned subsidiary Lantheus Alpha Therapy, LLC sold 78,145 shares of CATX common stock on August 31, 2026, at a weighted average price of $3.143 per share. After this open-market sale, the entity reported holding 11,599,194 CATX shares, adjusted to reflect a prior 1-for-10 reverse stock split effective June 14, 2024. No Rule 10b5-1 trading plan is reported for this transaction.
Perspective Therapeutics director Maria E. Martinez received a grant of stock options, giving her the right to buy 50,000 shares. The award, approved by the board as her annual 2026 equity grant, was granted on March 2, 2026 and carries a zero exercise price. The option vests in full on March 2, 2027, as long as she continues serving through that date.
Morich Frank reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. director Frank Morich received a grant of stock options covering 50,000 shares as his annual equity award for 2026. The Board of Directors approved the grant on January 26, 2026, with a grant date of March 2, 2026.
The option vests in full on March 2, 2027, provided Morich continues to serve through that date. Following this grant, he holds 50,000 stock options directly, reflecting a standard equity compensation award rather than an open-market share purchase or sale.
Williamson Robert F III reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. director Robert F. Williamson III reported receiving a grant of stock options representing 50,000 shares on March 2, 2026. The award was approved by the board on January 26, 2026 as his annual equity grant for 2026 and will vest in full on March 2, 2027, provided he continues serving through that date.
HENSON HEIDI reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics director Heidi Henson was granted a stock option covering 50,000 shares on March 2, 2026. The grant was approved by the board as her annual 2026 equity award. The option vests in full on March 2, 2027, if she continues serving through that date.
Perspective Therapeutics director receives 2026 stock option grant. Director Lori A. Woods was granted a stock option to buy 50,000 shares at an exercise price of $0.0000 per share as her annual equity award for 2026. The option vests in full on March 2, 2027, assuming she continues to serve through the vesting date.
Spoor Johan M. reported acquisition or exercise transactions in this Form 4 filing.
Perspective Therapeutics, Inc. reported that Chief Executive Officer Johan M. Spoor was granted stock options covering 735,000 shares on the March 2, 2026 grant date. The award, approved by the board on January 26, 2026, represents his annual 2026 equity grant. The options vest in 48 substantially equal monthly installments starting one month after the grant date, contingent on his continued service.
Perspective Therapeutics reported that Chief Accounting Officer Jonathan Robert Hunt received a grant of stock options representing the right to buy 90,000 shares, with a grant date of March 2, 2026. These options were approved by the board’s compensation committee as his annual equity award for 2026.
The options have a stated exercise price of $0.0000 per share and vest over four years in 48 substantially equal monthly installments starting one month after the grant date, conditioned on his continued service with the company.
Perspective Therapeutics, Inc. reported that Chief Medical Officer Markus Puhlmann received a grant of stock options covering 150,000 shares on the grant date of March 2, 2026. The options were approved by the compensation committee as his annual equity award for 2026 and have an exercise price of $0.0000 per share.
The option award vests and becomes exercisable over four years in 48 substantially equal monthly installments, starting one month after the grant date, so long as he continues serving the company on each vesting date. This is a routine equity compensation grant rather than an open‑market share purchase or sale.
Perspective Therapeutics, Inc. (CATX) reported an insider stock purchase by its Chief Accounting Officer on a Form 4. On 11/13/2025, the officer acquired 11,000 shares of common stock in an open market transaction coded “P” for purchase. The weighted average price paid was $2.0268 per share, with individual trades executed in a range from $2.0235 to $2.0300. Following this transaction, the officer beneficially owns 59,800 shares of Perspective Therapeutics common stock held directly.
Perspective Therapeutics (CATX) director Robert F. Williamson, III reported a Form 4 purchase of common stock. On 11/12/2025, he bought 9,498 shares (transaction code P) at $2.10 per share.
Following the transaction, the filing shows 9,864 shares held indirectly via the RFW3 Revocable Trust and 108,982 shares held directly. This reflects insider open-market buying and updates his reported holdings.